ARCHIVES

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Vermont Cancer Center’s NCI Core Grant Renewed.

May 11, 2001

Philadelphia Group Begins BMT Trial for Breast Cancer

April 5, 1991

NCCS Networker Volume 3 Issue 1, Winter 1989

January 13, 1989

Recalcitrant Cancer Bill Heading To Senate May Face Hold in the Lame Duck Session

November 16, 2012